AllSci News
ASCO: BMS's CELMoD mezigdomide reduces progression risk by 52% in Phase III multiple myeloma trial
Bristol Myers Squibb (NYSE: BMY) reported that mezigdomide, its oral cereblon E3 ligase modulator (CELMoD), cut the risk of disease progression or death by...
Lilly strikes USD 3.05b multi-program licensing collaboration with China's Haisco Pharma
Eli Lilly (NYSE: LLY) has struck a multi-program licensing and research collaboration with Haisco Pharmaceutical Group (SZSE: 002653) worth up to USD 3.05...
Gilead terminates early study for BTLA agonist in rheumatoid arthritis due to efficacy concerns
Gilead Sciences (Foster City, California, USA) has terminated its Phase Ib clinical trial of GS-0272, a selective B and T Lymphocyte Attenuator (BTLA)...
ASCO: D3 Bio shows off elisrasib's 78% response rate in first-line KRAS G12C lung cancer
D3 Bio reported response rates above 78% for elisrasib in previously untreated KRAS G12C–mutant non-small cell lung cancer at ASCO 2026, a result that, if...
ASCO: Eli Lilly's selpercatinib reduces disease recurrence risk by 83% in Phase III for RET fusion-positive lung cancer
Eli Lilly (NYSE: LLY) reported that selpercatinib (Retevmo) cut the risk of disease recurrence or death by 83% versus placebo in early-stage RET...
ASCO: CSPC's HER2 BsAb achieves 62.4% CR in Phase III breast cancer trial
CSPC Pharmaceutical Group (HKEX: 1093) reported Phase III data showing that anbenitamab (Ennituo), its HER2 bispecific antibody co-developed with Jiangsu...
ASCO: J&J's Rybrevant Faspro shows 42% response rate in pivotal head and neck cancer study
Johnson & Johnson (NYSE: JNJ) reported pivotal Phase Ib/II data showing that subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) produced a...
Johnson & Johnson's apalutamide plus hormone therapy reduces metastasis risk in Phase III prostate cancer trial
Johnson & Johnson reported Phase III data on Saturday showing that apalutamide (Erleada) added to hormone therapy before and after localized prostate cancer...
Akeso's ivonescimab beats tislelizumab in Phase III squamous NSCLC overall survival trial
Akeso (HKEX: 9926.HK) reported on Saturday that ivonescimab, its PD-1/VEGF bispecific antibody, cut the risk of death by 34% compared with a PD-1 inhibitor...
Lunai Bioworks and BrainStorm Therapeutics launch foundation-funded Parkinson's and rare epilepsy AI collaboration
Lunai Bioworks and BrainStorm Therapeutics have launched a foundation-funded neurology collaboration pairing AI-driven target discovery with human brain...
ASCO: Dizal's sunvozertinib produces Phase III goods in EGFR exon 20 insertion NSCLC
Dizal Pharmaceutical (SSE: 688192) reported that sunvozertinib (Zegfrovy) cut the risk of progression or death by 35% versus platinum-doublet chemotherapy...
FDA approves AstraZeneca’s Imfinzi combined with BCG for high-risk non-muscle-invasive bladder cancer
AstraZeneca announced that the US FDA has approved Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy for adult…
CSPC receives AZ's USD 1.2b upfront from long-acting peptide collaboration
AstraZeneca has confirmed receipt of a USD 1.2 billion upfront payment by CSPC Pharmaceutical Group (HKEX: 1093) under a strategic collaboration and license...
China approves CSPC’s HER2 BsAb Ennituo for gastric cancer post-Herceptin
China’s National Medical Products Administration has granted marketing authorization to Ennituo (anbenitamab; SYS6092; KN026 ), a recombinant humanised bispecific antibody co-developed by…
Merck’s calderasib KRAS G12C inhibitor gains FDA Breakthrough Therapy designation for metastatic NSCLC
Merck (NYSE: MRK) announced receipt of US FDA Breakthrough Therapy Designation (BTD) for calderasib (MK-1084), an oral next-generation KRAS G12C covalent inhibitor.…
The AllSci Brief
Systematic R&D and deal news. Daily.